ENOV

Enovis Corporation

Fundamental data last updated:September 17, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Devices

Exchange

NYSE

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.

 


VALUATION

P/E

-1.15

Market Cap ($M USD)

$1.33B

Forward P/E

5.25

PEG

0.04

PRICE TO SALES

0.58

PRICE TO BOOK

0.89

EV / EBITDA

-14.02

5-Year Average P/E

Free Cash Flow Yield

2.71%

DCF Value

$-115.64

Graham Number

N/A

Price to FCF

36.92

EV to FCF

75.26

Earnings Yield

-86.91%

FCF Yield

2.71%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$20.02

Next Year EPS Growth Estimate

$4.39

Next Year Revenue Growth Estimate

$2.59B

Return on Equity (ROE)

-60.13%

FREE CASH FLOW

Operating Margin

2.70%

Debt-to-Equity

0.93

Piotroski F-Score

4

Altman Z-Score

0.17

Return on Invested Capital (ROIC)

1.91%

Current Ratio

2.04

Quick Ratio

1.05

Net Debt to EBITDA

-7.14

Interest Coverage

1.08

Gross Profit margin

56.81%

FCF PER SHARE

$0.63

REVENUE PER SHARE

$40.12

Gainseekers Quantitative Analysis

Summary

The market seems to be mispricing Enovis Corporation significantly. With a DCF value deeply negative and a Graham Number unavailable, the stock’s valuation appears disconnected from traditional metrics. The Forward P/E of 6.04 suggests some optimism for future earnings, yet the negative Earnings Yield and Altman Z-score highlight financial distress and potential insolvency risks. Despite a “Buy” consensus, the company’s financial health is precarious, with a troubling ROIC of -34.92% and an alarming operating margin of -49.41%. This paints a picture of a company struggling to convert its operations into profitability.

AI Exposure / Tech Reliance

Operating within the Industrials sector, Enovis Corporation is well-positioned to leverage AI and modern technology shifts. As a player in the Industrial Machinery industry, the integration of AI can enhance operational efficiency and product innovation. However, the company's current financial struggles may hinder its ability to invest in these advancements effectively.

The Bull Case

For the value or GARP investor, Enovis presents an intriguing opportunity. The Forward PEG ratio of 0.05 indicates potential undervaluation relative to expected growth. A Piotroski F-Score of 5 suggests moderate financial health, while a Gross Profit Margin of 60.5% reflects strong pricing power. The company's ability to generate free cash flow, albeit modestly, with a yield of 2.35%, hints at underlying capital efficiency that could be harnessed if management can stabilize operations.

The Bear Case

Enovis faces significant structural risks that cannot be ignored. The negative EPS and Return on Equity of -60.13% are glaring red flags, indicating severe profitability issues. The Altman Z-score of -0.27 suggests a high risk of bankruptcy, while the negative EV to EBITDA ratio underscores operational inefficiencies. Despite a reasonable Debt/Equity ratio, the company's inability to cover interest expenses, as shown by the negative interest coverage, highlights a precarious financial position that could deter cautious investors.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$45.80

Institutional Ownership %

1-Year Beta

1.52

Insider Buying % (6 Mo)

Distance to 52-Week High

59.81%

Distance to 52-Week Low

8.85%

EARNINGS SURPRISE %

8.54%

50-DAY SMA

$24.05

200-DAY SMA

$26.97

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.